STARTUP PROFILE

Merge Labs

COUNTRY

USA

FOUNDED

2025

CATEGORY

Brain-Computer Interface

Exploring gene-therapy-enhanced, high-bandwidth, ultrasound-based brain-computer interfaces to enable seamless human–AI integration.

Visit website →

← Back to Startups

•

Neurofounders Insights

$ Funding -

Seed

MODALITY

Ultrasound

FORM FACTOR

Other

INTERFACE DEPTH

Non-invasive

INDICATION

Other

TARGET USER

Other

REGULATORY STAGE

Preclinical

Merge Labs represents a highly speculative attempt to combine ultrasound BCI concepts with gene-therapy-style enhancement and human–AI integration narratives. It is best viewed as frontier research ambition rather than a near-term commercial neurotechnology company.

Related companies

Surf Therapeutics

Forest Neurotech

•

Mentioned in Market Notes

MOST RECENT COVERAGE

No items found.

Articles featuring

Merge Labs

BCI Enters a New Funding Stage

A 17-company BCI snapshot shows $1.75B raised in the last 12 months, exceeding prior cumulative funding for the same set. The gains remain concentrated among a small number of firms.

Inside Merge Labs: BCI’s Biggest New Competitor

Merge Labs launches with $250M in funding to pursue non-implant, ultrasound-based BCIs. The move contrasts with capital clustering around invasive platforms and reframes where early BCI risk is being underwritten.

Where Sam Altman’s Merge Labs Could Fit in the Brain-Computer Interface Race

A new entrant is forming in the brain–computer interface space with unusually deep capital, strong AI ties, and ambitions that may extend beyond medicine, adding a fresh dynamic to an already competitive neurotech field.